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High HIV Incidence among  
Male Injection Drug Users in Delhi, India 
RESEARCH
UPDATE
JUNE 2013
India has a large injection drug user (IDU) population es-
timated at 177,000. The overall national HIV prevalence 
is around 7.2 percent in this group, which is the highest 
among all key populations in the country including ante-
natal care attendees, female sex workers, men who have 
sex with men and patients at sexually transmitted infec-
tion (STI) clinics.1, 2 While there is information available 
on HIV prevalence from different regions of the country, 
there is limited HIV incidence data among IDUs in India. 
In collaboration with Arise—Enhancing HIV Prevention 
Programs for At-Risk Populations, the Population Council 
initiated a prospective cohort study at five centers oper-
ated by Sahara Centre for Rehabilitation and Residential 
Care (SAHARA) in Delhi to examine HIV incidence and 
behavior change pre-introduction (control phase) and 
post-introduction (intervention phase) of HIV prevention 
services among IDUs. The study entails three rounds 
of data collection: baseline, follow-up visit 1 (FV1) and 
follow-up visit 2 (FV2) at the end of the study. Here we 
report the HIV incidence and correlates of incident HIV 
infections in the HIV-negative male IDUs cohort during the 
control phase. 
Study Methodology 
The baseline assessment was undertaken from May to 
October 2011 at five sites operated by SAHARA within 
Delhi. Participants were recruited through peer-referral 
(26.3 percent), targeted outreach by outreach workers 
(53.6 percent), and walk-ins (20.1 percent). Eligibility cri-
teria included being at least 18 years of age, residing in 
and around Delhi, and having injected drugs at least once 
in the last three months. A total of 3,792 males, including 
10 transgender, were recruited into the study. As very few 
female IDUs (n=26) were recruited in the study at base-
line, they have been excluded from the analysis. Only HIV 
negative male IDUs have been included in the incidence 
analysis. Trained research interviewers administered a 
close-ended questionnaire in Hindi to collect data on 
socio demographic characteristics, injecting practices, 
sexual behaviours, knowledge of HIV and utilization of 
harm reduction services. 
HIV serostatus at baseline was determined using NACO 
guidelines using rapid tests: HIV-negative status was 
based on a single highly sensitive rapid test and a pos-
itive result on two additional confirmatory rapid tests. 
At FV1, all HIV-negative male IDUs were tested using a 
fourth generation Antigen-Antibody test followed by a 
confirmatory Western Blot Assay. For participants who 
tested positive on Western Blot at FV1, their HIV-negative 
status at baseline was confirmed to rule out any window 
period HIV infection at baseline using a fourth generation 
Antigen-Antibody test on a stored serum sample. For 
participants with a negative or indeterminate result on 
the Western blot test at FV1, a plasma HIV PCR RNA test 
was conducted on the FV1 plasma sample to identify any 
window period infection at FV1. 
Analysis
HIV incidence rate was calculated over the control phase 
(date of FV1–date of baseline) by dividing the number 
of new infections by the total person-years of follow-up. 
Sero-conversion date was taken to be the date of HIV test 
at FV1 visit. Bivariate and multivariate analyses using Cox 
proportional hazard ratios were conducted to determine 
behavioral factors associated with incident HIV infections 
after controlling for age, education, marital status and 
accommodation.
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Study Population
Of the 2,790 eligible male HIV-negative IDUs recruited at 
baseline, 1,880 (67.4 percent) HIV-negative male IDUs 
returned for their FV1 visit. Among those, HIV testing was 
conducted for 1,806 (96 percent) and behavioral survey 
completed. The median follow-up time among partici-
pants was 9.7 months (IQR: 8.1, 11.1). The median age 
was 28 years [IQR: 23, 38]. About one-half (47.7 percent) 
were illiterate, and 53.5 percent were never married. 
IDUs were living with family or relatives (43.9 percent), liv-
ing on the street or slum (39.5 percent) or living in rented 
home or were a paying guest (16.6 percent).
Key Findings
High HIV incidence among male IDUs in Delhi
A total of 112 new HIV infections occurred over a cumula-
tive 1,443.76 person-years of follow-up resulting in an in-
cidence rate of 7.76 new infections per 100 person-years 
(95 percent CI: 6.45–9.34).
Risky injection practices were common among 
newly HIV-infected IDUs
Among the 112 newly HIV-infected participants, 74 
percent (n=83) reported risky injection behaviorsi in the 
last month preceding FV1. These high-risk practices in 
conjunction with the high HIV prevalence are fueling the 
HIV incidence. 
Risky injection practices associated with higher 
risk of HIV
On multivariate analysis, after controlling for age, educa-
tion, marital status and accommodation, risky injection 
behaviors (Hazard risk ratio [HRR] 2.76; 95 percent CI 
1.54–4.93), injecting smack/brown sugar (HRR: 2.43; 95 
percent CI: 1.53–3.87) were significantly associated with 
a higher risk of new infections. Injection with tranquilizers 
were associated with a lower risk of new infections (HRR: 
0.53; 95 percent CI: 0.32–0.86; p=0.01). 
iA 5-item ‘Risky Injection Behavior’ index was derived from various 
injection practices in the last one month: (i) Using needles or syringes 
previously used by someone else; (ii) Back/ front loading/splitting drugs 
(iii) Shared vial, cooker, container, cotton, filter or water; (iv) Receiving 
an injection with syringe filled by someone else; and (v) Drawing up 
drugs from a common container.
Sex partners at high risk of HIV infection
Although sexual activity was not associated with risk of 
incident infections, of the 112 participants with new in-
fections, 20.5 percent reported unsafe sex with a female 
partner in the three months preceding the survey. 
Conclusion and Program Implications
HIV transmission risk remains high among IDUs in Delhi 
despite targeted prevention interventions for this popula-
tion. The incidence of 7.76 per 100 person-years among 
male IDUs in Delhi is higher than other cities with estab-
lished HIV epidemic among IDUs such as St. Petersburg, 
Russia (4.5 per 100 person-years) and Bangkok, Thailand 
(5.8 per 100 person-years), but is comparable to the 
incidence among IDUs in Xinjiang, China (8.8 per 100 
person-years).3–5 
Despite the widespread availability of free sterile needles 
and syringes from needle exchange programs (NSEP) and 
targeted interventions with harm reduction messages, 
HIV risk is primarily associated with risky drug injection 
practices. Only a small proportion of our cohort reported 
accessing NSEP services and only 10 percent report-
ed accessing opioid substitution therapy in the month 
preceding the survey. Therefore, targeted intervention 
programs must find ways to: i) increase regular access 
to harm reduction services; and ii) that use of services 
actually translates to changed behaviors. 
This study also demonstrates that a large number of IDUs 
can be enrolled into a prevention study with reasonable 
rate of follow-up. Thus, this population should be consid-
ered for future HIV prevention trials.
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